Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating

ENGLISH
|
JAPANESE
|
CONNECT WITH US:

Jan 26, 2023 13:16 JST

Source: Prenetics Global Limited

Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating

Target Price at USD7.00

HONG KONG, Jan 26, 2023 - (ACN Newswire) - It is reported that Cantor Fitzgerald initiated coverage on Prenetics Global (PRE.US) with "Overweight" rating and target price at USD7.00.

Cantor Fitzgerald holds a favorable view of the consumer and clinical testing markets, with Prenetics' focus on diagnostic and preventive testing coupled with personalized and primary care facilities to address a global market opportunity of over $200 billion. In addition, Cantor Fitzgerald believes its commercialization strategy in rolling out tests both via B2C and B2B in the future, depending on which avenue will result in the broadest adoption with the lowest amount of operating expenses, is unique and sound. Prenetics looks to add new tests to its platform through acquisitions and partnerships, resulting in faster time to market and a comprehensive healthcare ecosystem in a not-so-distant future.

Meanwhile, with Prenetics' ecosystem coming together and being able to uniquely demonstrate profitability given its lower operating expenses and R&D expenses relative to peers, Cantor Fitzgerald thinks Prenetics' shares are also attractively valued.

In the near term, Prenetics will focus on Hong Kong, Southeast Asia and the UK, where the company has strong leadership teams in place and benefits from little to no competition, most notably in Asia.

Source: Prenetics Global Limited
Sectors: BioTech, Healthcare & Pharm

Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Release

HKTDC

The 26th Hong Kong Forum marks successful completion
Dec 03, 2025 22:44 JST

Anime Tokyo Station

Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15
Dec 03, 2025 11:30 JST

Eisai

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Dec 03, 2025 00:01 JST

NEC Corporation

NEC Launches AI Agent Service in Japan to Automate Procurement Negotiations Using AI
Dec 02, 2025 23:43 JST

Fujitsu develops new technology to support human-robot collaboration
Dec 02, 2025 23:26 JST

Fujitsu establishes international consortium to tackle disinformation/misinformation and new AI risks
Dec 02, 2025 22:55 JST

Fujitsu achieves high-precision, long-duration molecular dynamics simulation for all-solid-state battery interphases with over 100,000 atoms
Dec 01, 2025 23:04 JST

Fujitsu develops multi-AI agent collaboration technology to optimize supply chains, launches joint trials
Dec 01, 2025 22:43 JST

Fujitsu launches 'Fujitsu Accelerator Program for SPORTS' to create new value through Sports x Technology
Dec 01, 2025 22:14 JST

Eisai

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 28, 2025 23:00 JST

NEC Corporation

JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Nov 28, 2025 19:41 JST

Mitsubishi Heavy Industries, Ltd.

MHI Publishes "MHI REPORT 2025" and "SUSTAINABILITY DATABOOK 2025"
Nov 28, 2025 19:05 JST

Sharp Corporation

Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST

Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Nov 28, 2025 18:01 JST

Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Nov 28, 2025 17:28 JST

NEC Corporation

NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST

Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST

Mitsubishi Electric Building Solutions Corporation

World's first ever spiral escalator renewal project conducted at a commercial facility in Mexico
Nov 27, 2025 11:00 JST

Eisai

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST

Fujitsu accelerates blue carbon certification with ocean digital twin technology
Nov 26, 2025 19:05 JST

More Latest Release >>